Aevi Genomic Medicine Inc (GNMX) Expected to Post Earnings of -$0.16 Per Share
Brokerages expect Aevi Genomic Medicine Inc (NASDAQ:GNMX) to announce earnings per share (EPS) of ($0.16) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aevi Genomic Medicine’s earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.15). Aevi Genomic Medicine reported earnings per share of ($0.23) in the same quarter last year, which suggests a positive year over year growth rate of 30.4%. The business is expected to announce its next earnings report on Thursday, November 1st.
On average, analysts expect that Aevi Genomic Medicine will report full-year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.57). For the next fiscal year, analysts expect that the firm will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.27) to ($0.56). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Aevi Genomic Medicine.
Aevi Genomic Medicine (NASDAQ:GNMX) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01.
In other news, Director Sol J. Barer bought 2,551,020 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were purchased at an average price of $0.96 per share, for a total transaction of $2,448,979.20. Following the acquisition, the director now directly owns 1,028,032 shares of the company’s stock, valued at approximately $986,910.72. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 11.70% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its position in shares of Aevi Genomic Medicine by 515.8% during the 4th quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 78,400 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Aevi Genomic Medicine by 4,715.1% during the 1st quarter. JPMorgan Chase & Co. now owns 101,118 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 99,018 shares in the last quarter. Finally, Wedbush Securities Inc. acquired a new stake in shares of Aevi Genomic Medicine during the 2nd quarter valued at about $233,000. Institutional investors own 21.56% of the company’s stock.
GNMX traded down $0.03 during trading on Monday, hitting $1.26. The stock had a trading volume of 71,423 shares, compared to its average volume of 142,853. The company has a market capitalization of $75.36 million, a PE ratio of -1.52 and a beta of 0.99. Aevi Genomic Medicine has a 12 month low of $0.83 and a 12 month high of $2.65.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Featured Story: Discover Your Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.